Recombinant Human B7-1/CD80 Protein, ≥95% (SDS-PAGE), high purity

Features and benefits
  • Expression System: HEK293
  • Accession #: P33681
  • Protein Tag: C-His
  • Bioactivity: Immobilized Recombinant Human B7-1/CD80 Protein (rp144120) at 2.0 μg/mL can bind Recombinant human CTLA-4 with a linear range of 7.0 - 62.0 ng/mL. The EC50 for this effect is 23.47 ng/mL.
  • Endotoxin Concentration: <0.1 EU/μg
Item Number
rp144120
Grouped product items
SKUSizeAvailabilityPrice Qty
rp144120-10μg
10μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
rp144120-50μg
50μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$139.90
rp144120-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,599.90

Animal Free, ≥95% (SDS-PAGE), Active, 293F, C-His tag, 35-242 aa

Basic Description

Product NameRecombinant Human B7-1/CD80 Protein, ≥95% (SDS-PAGE), high purity
SynonymsActivation B7-1 antigen | B7 | BB1 | CTLA-4 counter-receptor B7.1 | Activation B7-1 antigen | B lymphocyte activation antigen B7 | B7 | B7-1 | B7-1 antigen | B7.1 | BB1 | CD28 antigen ligand 1 | CD28LG | CD28LG1 | CD80 | CD80 antigen | CD80 antigen (CD28
GradeActiBioPure™, Animal Free, Azide Free, Bioactive, Carrier Free
Product Description

Purity
≥95% (SDS-PAGE)
Endotoxin level
<0.1 EU/μg
Function
Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28 or CTLA-4 to this receptor.

Specifications & PurityActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE)
Purity≥95% (SDS-PAGE)
BioactivityImmobilized Recombinant Human B7-1/CD80 Protein (rp144120) at 2.0 μg/mL can bind Recombinant human CTLA-4 with a linear range of 7.0 - 62.0 ng/mL. The EC50 for this effect is 23.47 ng/mL.
Endotoxin Concentration<0.1 EU/μg
Expression SystemHEK293
SpeciesHuman
Amino Acids35-242 aa
SequenceVIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNHHHHHH
Protein TagC-His
Accession #P33681
Predicted molecular weight25 kDa
SDS-PAGE40 - 55 kDa, under reducing conditions; 40 - 55 kDa, under non-reducing conditions.

Product Specifications

FormLyophilized
ReconstitutionReconstitute in sterile water to a concentration of 0.1-0.5 mg/ml.
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -20~-80℃ for more than 1 year. Upon delivery aliquot. Avoid freeze/thaw cycle.

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al..  (2004)  The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)..  Genome Res,  14  (10B): (2121-7).  [PMID:15489334]
2. Vicente Rabaneda EF, Herrero-Beaumont G, Castañeda S.  (2013)  Update on the use of abatacept for the treatment of rheumatoid arthritis..  Expert Rev Clin Immunol,  (7): (599-621).  [PMID:23899231]
3. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA.  (1991)  CTLA-4 is a second receptor for the B cell activation antigen B7..  J Exp Med,  174  (3): (561-9).  [PMID:1714933]
4. Selvakumar, A A and 5 more authors..  (1992)  Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7..  Immunogenetics,      [PMID:1377173]
5. Freeman, G J GJ and 8 more authors..  (1991)  Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7..  The Journal of experimental medicine,    (1):   [PMID:1714935]
6. Freeman, G J GJ and 5 more authors..  (1989)  B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells..  Journal of immunology (Baltimore, Md. : 1950),    (15):   [PMID:2794510]
7. Lanier, L L LL and 7 more authors..  (1995)  CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL..  Journal of immunology (Baltimore, Md. : 1950),    (1):   [PMID:7527824]
8. Vandenborre, K K and 5 more authors..  (1999)  Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation..  Immunology,      [PMID:10583602]
9. Ikemizu, S S and 7 more authors..  (2000)  Structure and dimerization of a soluble form of B7-1..  Immunity,      [PMID:10661405]
10. Gottlieb, Alice B AB and 8 more authors..  (2004)  Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis..  Clinical immunology (Orlando, Fla.),      [PMID:15093549]
11. Czuczman, Myron S MS and 13 more authors..  (2005)  Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,    (1):   [PMID:15994148]
12. and Kremer, Joel M JM..  (2005)  Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis..  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,      [PMID:16357751]
13. Hervey, Pauline S PS and Keam, Susan J SJ..  (2006)  Abatacept..  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,      [PMID:16573350]
14. Muzny, Donna M DM and 113 more authors..  (2006)  The DNA sequence, annotation and analysis of human chromosome 3..  Nature,    (27):   [PMID:16641997]
15. Weyand, Cornelia M CM and Goronzy, Jörg J JJ..  (2006)  T-cell-targeted therapies in rheumatoid arthritis..  Nature clinical practice. Rheumatology,      [PMID:16932686]
16. and Scheinfeld, Noah N..  (2006)  Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists..  The Journal of dermatological treatment,      [PMID:16971318]
17. Tedesco Silva, Helio H, Pinheiro Machado, Paula P, Rosso Felipe, Claudia C and Medina Pestana, Jose Osmar JO..  (2006)  Immunotherapy for De Novo renal transplantation: what's in the pipeline?.  Drugs,      [PMID:16978033]
18. Vincenti, Flavio F and Luggen, Michael M..  (2007)  T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation..  Annual review of medicine,      [PMID:17020493]
19. Nogid, Anna A and Pham, David Q DQ..  (2006)  Role of abatacept in the management of rheumatoid arthritis..  Clinical therapeutics,      [PMID:17212998]
20. Leonard, J P JP and 14 more authors..  (2007)  A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma..  Annals of oncology : official journal of the European Society for Medical Oncology,      [PMID:17470451]
21. Kakoulidou, M M, Giscombe, R R, Zhao, X X, Lefvert, A K AK and Wang, X X..  (2007)  Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation..  Scandinavian journal of immunology,      [PMID:17953528]
22. Reynolds, Jennifer J, Shojania, Kam K and Marra, Carlo A CA..  (2007)  Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis..  Pharmacotherapy,      [PMID:18041889]
23. Maxwell, Lara J LJ and Singh, Jasvinder A JA..  (2010)  Abatacept for rheumatoid arthritis: a Cochrane systematic review..  The Journal of rheumatology,      [PMID:20080922]
24. Kleinpeter, Patricia and 20 more authors..  (2019)  By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1..  Journal of virology,    (1):   [PMID:30918073]

Solution Calculators